These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prizidilol (SKF 92657) in primary hypertension.
    Author: Karlberg BE, Larsson R, Ohman KP.
    Journal: Clin Sci (Lond); 1981 Dec; 61 Suppl 7():461s-464s. PubMed ID: 7188585.
    Abstract:
    1. Prizidilol (SKF 92657), a new antihypertensive drug with combined precapillary vasodilator and non-selective beta-adrenoceptor-blocking actions, was given to 24 patients with essential hypertension in a placebo-controlled, dose-titration study, Incremental doses from 200 to 800 mg were given once daily. Supine and standing blood pressure measured 24--27 h after drug intake was reduced during treatment with prizidilol (400--800 mg/day). Slight but significant decreases in heart rate were seen after moderate doses (mean: 447 mg once daily) of prizidilol. A more pronounced blood pressure reduction was noticed 2--7 h after drug administration. 2. Maximal blood pressure reduction coincided with peak plasma concentration of prizidilol, which was measured by a newly developed assay. 3. Plasma renin activity and 24 h urinary excretion of aldosterone and methoxycatecholamines were reduced after the highest doses (mean: 700 mg once daily) of prizidilol. 4. Prizidilol was well tolerated, although dizziness and tiredness were reported by four patients and oedema by two.
    [Abstract] [Full Text] [Related] [New Search]